Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma

pharmafile | November 8, 2019 | News story | Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma 

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line maintenance treatment of multiple myeloma in adult patients not treated with stem cell transplantation.

In a Phase 3 study incorporating 706 multiple myeloma patients who had completed 6-12 months of initial therapy and achieved a partial response or better, Ninlaro demonstrated a “statistically significant” improvement in progression free survival compared to placebo, meeting its primary endpoint.

The safety profile of the drug was also found to be in line with previous data.

“We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout from the TOURMALINE clinical trial programme,” commented Dr Phil Rowlands, Head of the Oncology Therapeutic Area Unit at Takeda. “We remain committed to bringing this convenient and well-tolerated treatment option to patients.”

The company confirmed it would unveil the full results from the study at an upcoming medical meeting.

Matt Fellows

Related Content

Heidelberg Pharma gains FDA ODD for ATAC candidate

Heidelberg Pharma has announced that it has gained Orphan Drug Designation (ODD) from the US …

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …

GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma

GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head …

Latest content